Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies

  1. C. F. LINDBOE1,*,
  2. G. VON DER OHE1,
  3. S. H. TORP2

Article first published online: 25 JUL 2003

DOI: 10.1034/j.1600-0463.2003.1110505.x

Issue

APMIS

APMIS

Volume 111, Issue 5, pages 567–570, May 2003

Additional Information

How to Cite

LINDBOE, C. F., VON DER OHE, G. and TORP, S. H. (2003), Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. APMIS, 111: 567–570. doi: 10.1034/j.1600-0463.2003.1110505.x

Author Information

  1. 1

    Department of Pathology, Vest-Agder Hospital, Kristiansand, and

  2. 2

    Department of Pathology, Department of Laboratory Medicine, Norwegian University of Science and Technology, St. Olav's Hospital, Trondheim, Norway

*Christian Fredrik Lindboe, Department of Pathology, Vest-Agder Hospital, N-4604 Kristiansand S, Norway. e-mail: c.lindboe@c2i.net

  1. Received December 30, 2002.Accepted April 10, 2003.

Publication History

  1. Issue published online: 25 JUL 2003
  2. Article first published online: 25 JUL 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (48K)

Keywords:

  • Immunohistochemistry;
  • proliferation index;
  • Ki-67; MIB-1

Paraffin sections from 23 tumours were immunohistochemically stained with the following four Ki-67 equivalent antibodies: monoclonal MIB-1 (DAKO), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (DAKO). Ki-67 labelling indices were determined by counting in exactly the same area in each case. MIB-1 showed the highest labelling index in 21 of the 23 cases, and the mean MIB-1 index was approximately 30% higher than that of the other antibodies. The differences between MM1, NCL-Ki-67p and Rah Ki-67 were small and non-significant. There was a positive correlation between each of the four antibodies. As these findings may be of importance when the Ki-67 labelling index is used as a criterion for tumour grading or for clinical prognostication, this necessitate identification of the antibody used in every case.

View Full Article (HTML) Get PDF (48K)